Journal: BMC Pharmacology & Toxicology

Article Title: The pan-African natural products library compounds oleanolic acid, poinsettifolin B, and rhuschalcone III disrupt SARS-CoV-2 spike-host ACE2 interactions and SARS-CoV-2 replication

doi: 10.1186/s40360-026-01264-3

Figure Lengend Snippet: Docking scores and ΔG bind (Prime MM-GBSA) values of panel compounds towards the binding sites of two other SARS-CoV-2 targets: M pro (PDB ID: 7L0D) and RdRp (PDB ID:7BV2)

Article Snippet: This activity approached that of the positive control inhibitor remdesivir, which inhibited 85.8 ± 11.4% of virus replication at 10 μM, which in turn is consistent with its previously reported EC 50 of 7.3 μM by us in this assay [ ].

Techniques: Docking Assay, Binding Assay

Journal: BMC Pharmacology & Toxicology

Article Title: The pan-African natural products library compounds oleanolic acid, poinsettifolin B, and rhuschalcone III disrupt SARS-CoV-2 spike-host ACE2 interactions and SARS-CoV-2 replication

doi: 10.1186/s40360-026-01264-3

Figure Lengend Snippet: Dose-response curves of oleanolic acid ( A ), poinsettifolin B ( B ), and rhuschalcone III ( C ) indicating ability to inhibit SARS-CoV-2 replication in infected Vero cells (green) and cell viability in uninfected Vero cells (violet). In these experiments, control inhibitor remdesivir inhibited 85.8 ± 11.4% replication at 10 µM, consistent with its previously reported EC 50 of 7.3 µM in this assay

Article Snippet: This activity approached that of the positive control inhibitor remdesivir, which inhibited 85.8 ± 11.4% of virus replication at 10 μM, which in turn is consistent with its previously reported EC 50 of 7.3 μM by us in this assay [ ].

Techniques: Infection, Control

Journal: Toxicological Sciences

Article Title: Nonclinical safety assessment of SBT777101, a CAR-engineered regulatory T cell therapy for autoimmune diseases

doi: 10.1093/toxsci/kfag125

Figure Lengend Snippet: SBT777101 demonstrates minimal antigen-specific activation without impact on normal human cell survival. (A) Representative flow cytometry plots showing surface (top) and intracellular (bottom) binding of SBT777101 scFv-Fc (right) relative to isotype control (left) in SNU449 cells. (B) In vitro functional characterization using SNU449 cells ± CV-beads. Left: Mean ± SD CD69 expression (only SBT777101 data shown; no activation observed in UT controls). Data analyzed by two-way ANOVA with Sidak’s multiple comparisons test. Right: Cytotoxicity measured as the number of viable target cells remaining, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (C) Percentage of UT (top) or SBT777101 (bottom) Tregs expressing CD69 after 24-h co-culture with normal human primary cells or CV-beads (positive control). Data represent mean ± SD from three replicates. Independent experiments are separated by dashed vertical lines. Comparisons were made for media alone compared with in the presence of primary cells for each type and analyzed by two-tailed unpaired t -test. (D) Cytotoxicity (mean ± SD) of SBT777101 and UT Tregs against the same primary cell panel, normalized to no-Treg controls. Data analyzed by one-way ANOVA with Tukey’s multiple comparisons test. (E) Fold-change in CD71 expression (mean ± SD; relative to media control) across three donors after 72-h culture with media, CitP − SKNBE2 cells, CitP + SNU449 cells, human brain astrocytes (HBA), or CV-beads. CV beads were prepared in RPMI or AGM media as appropriate. Full lysis controls (B, D) represent target cells treated with Triton X-100. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. All experiments included 3 technical replicates. AGM, astrocyte growth medium; CitP, citrullinated protein; CV, citrullinated vimentin; HMEC, human mammary epithelial cells; NHBE, normal human bronchial epithelial cells; NHDF, normal human dermal fibroblasts; PrEC, prostate epithelial cells; RPTEC, renal proximal tubule epithelial cells; scFv, single-chain variable fragment; UT, untransduced.

Article Snippet: Primary human cells (mammary epithelial cells [HMEC; Lonza Cat#CC-2551], normal bronchial epithelial cells [NHBE; Lonza Cat#CC2451], renal proximal tubule epithelial cells [RPTEC; Lonza Cat#CC2553], prostate epithelial cells [PrEC; Lonza Cat#CC2555], hepatocytes [Lonza Cat#HUCPG], brain astrocytes [HBA; Neuromics Cat#HMP202], iPSC-derived myocytes [Tempo Bioscience Cat#1014], iPSC-derived cortical neurons [Tempo Bioscience Cat#201], and monocyte-derived macrophages [internally derived]) and the positive-control SNU449 cell line (ATCC Cat#CRL-2234) were assessed for binding of the SBT777101 scFv by flow cytometry.

Techniques: Activation Assay, Flow Cytometry, Binding Assay, Control, In Vitro, Functional Assay, Expressing, Co-culture Assay, Positive Control, Two Tailed Test, Lysis